Suppr超能文献

多阶段自适应富集试验设计与亚组估计。

Multi-stage adaptive enrichment trial design with subgroup estimation.

机构信息

Department of Biostatistics, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

出版信息

J Biopharm Stat. 2020 Nov 1;30(6):1038-1049. doi: 10.1080/10543406.2020.1832109. Epub 2020 Oct 18.

Abstract

We consider the problem of estimating the best subgroup and testing for treatment effect in a clinical trial. We define the best subgroup as the subgroup that maximizes a utility function that reflects the trade-off between the subgroup size and the treatment effect. For moderate effect sizes and sample sizes, simpler methods for subgroup estimation worked better than more complex tree-based regression approaches. We propose a three-stage design with a weighted inverse normal combination test to test the hypothesis of no treatment effect across the three stages.

摘要

我们考虑了在临床试验中估计最佳亚组和检验治疗效果的问题。我们将最佳亚组定义为最大化反映亚组大小和治疗效果之间权衡的效用函数的亚组。对于中等效应大小和样本大小,较简单的亚组估计方法比更复杂的基于树的回归方法效果更好。我们提出了一个三阶段设计,使用加权逆正态组合检验来检验三个阶段内无治疗效果的假设。

相似文献

1
Multi-stage adaptive enrichment trial design with subgroup estimation.
J Biopharm Stat. 2020 Nov 1;30(6):1038-1049. doi: 10.1080/10543406.2020.1832109. Epub 2020 Oct 18.
2
Estimating the subgroup and testing for treatment effect in a post-hoc analysis of a clinical trial with a biomarker.
J Biopharm Stat. 2019;29(4):685-695. doi: 10.1080/10543406.2019.1633655. Epub 2019 Jul 4.
3
Design and analysis of biomarker-integrated clinical trials with adaptive threshold detection and flexible patient enrichment.
J Biopharm Stat. 2020 Nov 1;30(6):1060-1076. doi: 10.1080/10543406.2020.1832110. Epub 2020 Nov 11.
4
A two-stage adaptive clinical trial design with data-driven subgroup identification at interim analysis.
Pharm Stat. 2022 Sep;21(5):1090-1108. doi: 10.1002/pst.2208. Epub 2022 Mar 24.
5
Design considerations for two-stage enrichment clinical trials.
Biometrics. 2023 Sep;79(3):2565-2576. doi: 10.1111/biom.13805. Epub 2022 Dec 13.
6
Sample size re-estimation in adaptive enrichment design.
Contemp Clin Trials. 2021 Jan;100:106216. doi: 10.1016/j.cct.2020.106216. Epub 2020 Nov 24.
8
Optimal design for inference on the threshold of a biomarker.
Stat Methods Med Res. 2024 Feb;33(2):321-343. doi: 10.1177/09622802231225964. Epub 2024 Jan 31.
9
Optimized adaptive enrichment designs.
Stat Methods Med Res. 2019 Jul;28(7):2096-2111. doi: 10.1177/0962280217747312. Epub 2017 Dec 18.
10
Treatment evaluation for a data-driven subgroup in adaptive enrichment designs of clinical trials.
Stat Med. 2018 Jan 15;37(1):1-11. doi: 10.1002/sim.7497. Epub 2017 Sep 26.

本文引用的文献

1
Estimating the subgroup and testing for treatment effect in a post-hoc analysis of a clinical trial with a biomarker.
J Biopharm Stat. 2019;29(4):685-695. doi: 10.1080/10543406.2019.1633655. Epub 2019 Jul 4.
2
Biomarker threshold adaptive designs for survival endpoints.
J Biopharm Stat. 2018;28(6):1038-1054. doi: 10.1080/10543406.2018.1434191. Epub 2018 Feb 13.
3
Treatment evaluation for a data-driven subgroup in adaptive enrichment designs of clinical trials.
Stat Med. 2018 Jan 15;37(1):1-11. doi: 10.1002/sim.7497. Epub 2017 Sep 26.
4
Inference for multimarker adaptive enrichment trials.
Stat Med. 2017 Nov 20;36(26):4083-4093. doi: 10.1002/sim.7422. Epub 2017 Aug 10.
5
Overlapping Group Logistic Regression with Applications to Genetic Pathway Selection.
Cancer Inform. 2016 Sep 15;15:179-87. doi: 10.4137/CIN.S40043. eCollection 2016.
6
Tutorial in biostatistics: data-driven subgroup identification and analysis in clinical trials.
Stat Med. 2017 Jan 15;36(1):136-196. doi: 10.1002/sim.7064. Epub 2016 Aug 3.
7
Methods for identification and confirmation of targeted subgroups in clinical trials: A systematic review.
J Biopharm Stat. 2016;26(1):99-119. doi: 10.1080/10543406.2015.1092034.
8
A Simple Method for Estimating Interactions between a Treatment and a Large Number of Covariates.
J Am Stat Assoc. 2014 Oct;109(508):1517-1532. doi: 10.1080/01621459.2014.951443.
9
A regression tree approach to identifying subgroups with differential treatment effects.
Stat Med. 2015 May 20;34(11):1818-33. doi: 10.1002/sim.6454. Epub 2015 Feb 5.
10
Adaptive randomized phase II design for biomarker threshold selection and independent evaluation.
Chin Clin Oncol. 2014 Mar 1;3(1). doi: 10.3978/j.issn.2304-3865.2013.12.04.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验